BeiGene (BGNE) Stock Price, News & Analysis

+1.82 (+1.06%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
275,361 shs
Average Volume
203,834 shs
Market Capitalization
$16.54 billion
P/E Ratio
Dividend Yield
Price Target

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
45.8% Upside
$251.93 Price Target
Short Interest
1.93% of Shares Sold Short
Dividend Strength
News Sentiment
0.94mentions of BeiGene in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$10.22 M Sold Last Quarter
Proj. Earnings Growth
From ($8.20) to ($3.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars

Medical Sector

361st out of 921 stocks

Pharmaceutical Preparations Industry

158th out of 421 stocks

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

BeiGene (NASDAQ:BGNE) Price Target Raised to $254.00
Evaluating BeiGene: Insights From 6 Financial Analysts
BeiGene Becomes Oversold (BGNE)
4 Analysts Assess BeiGene: What You Need To Know
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.46 billion
Book Value
$35.12 per share


Free Float
Market Cap
$16.54 billion

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price target for 2024?

10 Wall Street research analysts have issued 1 year price objectives for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they predict the company's share price to reach $251.93 in the next year. This suggests a possible upside of 45.8% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2024?

BeiGene's stock was trading at $180.36 at the beginning of 2024. Since then, BGNE shares have decreased by 4.2% and is now trading at $172.85.
View the best growth stocks for 2024 here

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BGNE earnings forecast

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($2.41) EPS for the quarter, topping the consensus estimate of ($3.07) by $0.66. The firm earned $751.70 million during the quarter, compared to analyst estimates of $670.09 million. BeiGene had a negative trailing twelve-month return on equity of 21.70% and a negative net margin of 28.39%. The company's revenue was up 67.9% on a year-over-year basis. During the same period last year, the business earned ($3.34) earnings per share.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital International Investors (7.38%), Baillie Gifford & Co. (3.90%), Price T Rowe Associates Inc. MD (2.12%), Capital International Inc. CA (0.90%), Artal Group S.A. (0.42%) and Capital Group Private Client Services Inc. (0.22%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 5/19/2024 by Staff

From Our Partners